Cited 0 times in
이상지질혈증 치료 약제의 최신지견
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상학 | - |
dc.date.accessioned | 2018-03-26T17:02:06Z | - |
dc.date.available | 2018-03-26T17:02:06Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 2233-7431 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/157097 | - |
dc.description.abstract | Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | Korean Diabetes Association | - |
dc.relation.isPartOf | Journal of Korean Diabetes | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | 이상지질혈증 치료 약제의 최신지견 | - |
dc.title.alternative | Update on the Pharmacologic Agents for Dyslipidemia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | 이상학 | - |
dc.identifier.doi | 10.4093/jkd.2015.16.4.269 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J02878 | - |
dc.subject.keyword | Cholesterol ester transfer proteins | - |
dc.subject.keyword | Ezetimibe | - |
dc.subject.keyword | Fibric acids | - |
dc.subject.keyword | Human PCSK9 protein | - |
dc.subject.keyword | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keyword | Niacin | - |
dc.subject.keyword | Omega-3 fatty acids | - |
dc.contributor.alternativeName | Lee, Snag Hak | - |
dc.contributor.affiliatedAuthor | Lee, Snag Hak | - |
dc.citation.volume | 16 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 269 | - |
dc.citation.endPage | 275 | - |
dc.identifier.bibliographicCitation | Journal of Korean Diabetes, Vol.16(4) : 269-275, 2015 | - |
dc.identifier.rimsid | 41660 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.